Viread, Tenofovir Newswire

Viread, Tenofovir Newswire

Comprehensive Real-Time News Feed for Viread, Tenofovir (generic).

Results 1 - 20 of 146 in Viread, Tenofovir (generic)

  1. Tenofovir alafenamide approved for hepatitis B in EuropeRead the original story w/Photo

    Monday Jan 16 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  2. HIV Medications, Possibly Including PrEP, May Raise Susceptibility to SyphilisRead the original story w/Photo

    Monday Jan 16 | POZ

    The effects of antiretrovirals on certain mechanisms of the immune system may make individuals more susceptible to syphilis. These findings from a mathematical modeling study, which may apply to those taking ARVs as pre-exposure prophylaxis, or PrEP, in addition to those using them for HIV treatment, may help explain the recent surge in syphilis rates among men who have sex with men .

    Comment?

  3. European Commission Grants Marketing Authorization for Gilead's...Read the original story

    Wednesday Jan 11 | Customer Interaction Solutions

    European Commission Grants Marketing Authorization for Gilead's Vemlidy for the Treatment of Chronic Hepatitis B Virus Infection European Commission Grants Marketing Authorization for Gilead's Vemlidy for the Treatment of Chronic Hepatitis B Virus Infection Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vemlidy 25 mg, a once-daily tablet for the treatment of chronic hepatitis B virus infection in adults and adolescents . The marketing authorization allows for the marketing of TAF in the 28 countries of the European Union, Norway and Iceland.

    Comment?

  4. Drug and Device News January 2017Read the original story

    Saturday Jan 7 | P&T Community

    The FDA has approved Xultophy 100/3.6 . The product, a once-daily combination of Tresiba and Victoza , is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes that is in adequately controlled on less than 50 units of basal insulin daily or on less than or equal to 1.8 mg of liraglutide daily.

    Comment?

  5. Hep C Drug Sovaldi May Interact Harmfully With HIV Drug VireadRead the original story w/Photo

    Wednesday Dec 28 | POZ

    Sovaldi is included in the fixed-dose combination hep C regimens Harvoni and Epclusa and is also used in combination with other stand-alone tablets such as Daklinza and Olysio . Viread is included in Truvada , Atripla , Stribild and Complera .

    Comment?

  6. I'm Sticking It Out With GileadRead the original story w/Photo

    Tuesday Dec 27 | Seeking Alpha

    Competitors are not only battling Gilead on the Hep C and Hep B fronts, but they are also taking aim at the high growth area of HIV. Perhaps with the markets closed for the long Christmas weekend investors had a chance to think about their portfolio holdings and what they want to do with them for 2017.

    Comment?

  7. Gilead: Japan's HBV Approval Is A Major CoupRead the original story w/Photo

    Monday Dec 26 | Seeking Alpha

    In November Gilead received FDA and EC approval for Vemlidy, its next generation HBV drug. A few days ago Japan's Ministry of Health, Labor and Welfare also approved Vemlidy : Gilead Sciences, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare has approved VemlidyA 25mg, a once-daily treatment for suppression of viral replication in chronic hepatitis B patients with evidence of hepatitis B virus replication and abnormal liver function.

    Comment?

  8. Spring Bank Pharmaceuticals Registers Recent PIPE Shares For SaleRead the original story w/Photo

    Dec 19, 2016 | Seeking Alpha

    With topline results for its lead due in 1H 2017, the new year presents a number of potential upside and downside catalysts for the stock. Spring Bank Pharmaceuticals has registered for sale approximately $30 million in selling stockholder shares and warrants related to a PIPE it completed in November 2016.

    Comment?

  9. ContraVir expands mid-stage study of tenofovir prodrug analog into higher doseRead the original story w/Photo

    Dec 19, 2016 | Seeking Alpha

    ContraVir Pharmaceuticals broadens its ongoing Phase 2a study evaluating tenofovir exalidex against Gilead Sciences' tenofovir disoproxil fumarate in patients with chronic hepatitis B virus infection by increasing the highest planned dose to 150 mg/day from 100 mg/day. The 84-subject sequential dose escalation study is assessing once-daily doses of TXL for four weeks against 300 mg of TDF once daily.

    Comment?

  10. Co-morbidities are common and rising among people with HIV in the USRead the original story w/Photo

    Dec 19, 2016 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  11. ContraVir Expands Phase 2a Trial Of Tenofovir Exalidex (Formerly...Read the original story

    Dec 18, 2016 | BioSpace

    This head-to-head trial comparing TXL to tenofovir disoproxil fumarate is the first evaluation of TXL in chronically infected hepatitis B patients. ContraVir plans to begin evaluating TXL at 150 mg per day dosing and potentially higher dosing based on TXL's continued strong performance, to date, and following recent clearance by the independent data safety monitoring board .

    Comment?

  12. IDWeek 2016: Comorbidities Are Common and Rising Among People with HIVRead the original story w/Photo

    Dec 15, 2016 | HIV and Hepatitis

    People living with HIV are increasingly experiencing a range of non-AIDS-related comorbidities as the population ages, including cardiovascular disease, kidney impairment, and bone loss leading to fractures, according to research presented at the recent IDWeek 2016 meeting in New Orleans. Thanks to effective antiretroviral therapy , more HIV-positive people in the U.S. and Europe are surviving to older ages.

    Comment?

  13. Hepatitis C and HIV Medications Can Interact Adversely When Used TogetherRead the original story

    Dec 13, 2016 | Infection Control Today

    In the past few years, the normally reticent scientific community heralded as revolutionary new medications for hepatitis C, saying the drugs would bring a major shift in the treatment of the chronic and potentially fatal viral infection that affects 150 million people worldwide. They were right.

    Comment?

  14. Bad Combination: Hepatitis C and HIV Medications Can Interact Adversely When Used TogetherRead the original story

    Dec 13, 2016 | Newswise

    KINGSTON, R.I., December 13, 2016 - In the past few years, the normally reticent scientific community heralded as revolutionary new medications for Hepatitis C, saying the drugs would bring a major shift in the treatment of the chronic and potentially fatal viral infection that affects 150 million people worldwide. They were right.

    Comment?

  15. Some Africans Failing First-Line HIV Regimens Have Multidrug ResistanceRead the original story w/Photo

    Dec 2, 2016 | POZ

    Evidence of multidrug resistance is emerging among those failing first-line, tenofovir-based HIV regimens in sub-Saharan Africa. A significant proportion of this group who had resistance to an older class of antiretrovirals were also resistant to newer treatments.

    Comment?

  16. Gilead Has 1 More Trick Up Its SleeveRead the original story w/Photo

    Dec 2, 2016 | Seeking Alpha

    The fact that they have not purchased anyone yet is kind of a saving grace for that them as they can now get some better names at cheaper valuations. Gilead has yet to make a move on another company as investors wait patiently on results from some of the biopharma's pipeline studies.

    Comment?

  17. December 2001Read the original story w/Photo

    Nov 30, 2016 | POZ

    David Welch, 42, has the heart of a girl -- a 14-year-old one, to be exact. Together, they are blazing a trail for HIVers through the once-f... Two years after washington state started tracking HIV cases by name, experts remain split on whether public health or politics is best serve... Gary Norton, 53, lost a 12-year battle with AIDS on October 9. After serving on a U. S. Navy submari On October 26, Gilead's tenofovir became the only new anti-HIV drug to win FDA OK this year

    Comment?

  18. Fed TapeRead the original story w/Photo

    Nov 30, 2016 | POZ

    On October 26, Gilead's tenofovir became the only new anti-HIV drug to win FDA OK this year. The drug got the green light for use by anyone with HIV, despite an un-precedented -- and, to the small biotech and activists alike, improper -- advisory-committee rec that it be used only by those with drug resistance or advanced AIDS.

    Comment?

  19. AASLD 2016: Nucleic Acid Polymers Reduce HBsAg Levels and Improve Control of Hepatitis B VirusRead the original story w/Photo

    Nov 22, 2016 | HIV and Hepatitis

    The nucleic acid polymers REP 2139 and REP 2165 led to hepatitis B surface antigen reduction or clearance when combined with tenofovir and pegylated interferon, according to early results from a small study presented as a late-breaker at the AASLD Liver Meeting this month in Boston. This combination may potentially enable functional control of hepatitis B if confirmed in larger studies.

    Comment?

  20. Gilead's Myelofibrosis Pipeline Just Doesn't Stand OutRead the original story w/Photo

    Nov 17, 2016 | Seeking Alpha

    Gilead Sciences is methodically working through its late-stage clinical trials. Recently the company reported some top-line results from a pair of phase 3 clinical trials of momelotinib, the company's candidate for myelofibrosis treatment .

    Comment?